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The use of very low nicotine tobacco cigarettes is currently being investigated as a possible harm
reduction strategy. Here, we report the smoke chemistry, toxicity, and physical characteristics of very low
nicotine cigarettes that were made using blended tobacco processed through a supercritical CO2 ﬂuid
extraction, which resulted in elimination of 96% of nicotine content (denicotinized (denic) tobacco).
Three types of test cigarettes (TCs) were manufactured with tobacco ﬁller containing 100% denic tobacco
(TC100), 50% denic tobacco and 50% unextracted tobacco (TC50/50), and 100% unextracted tobacco (TC0).
Mainstream smoke (MS) was generated for measurement of 46 analytes and cytotoxicity and mutage-
nicity determination. Analysis of physical characteristics of TCs demonstrated they were well made with
<5% variability among cigarettes for most parameters measured. We observed signiﬁcant changes in the
levels of smoke constituents, including decreases in formaldehyde, nitrosamines, and phenol, and in-
creases in aliphatic hydrocarbons, aliphatic nitrogen compounds, aromatic amines, halogen compounds,
and metals. Use of denic tobacco resulted in changes in the chemical composition of MS, but these
changes did not modify biological activity as measured in the mutagenicity and cytotoxicity assays.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The majority of published studies investigating the effect of
varying nicotine levels in cigarettes on smoking behavior have used
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Inc. This is an open access article uHatsukami et al. (2010)] and Philip Morris USA (PM USA) denico-
tinized (denic) tobacco research cigarettes (RCs) [e.g., Benowitz
et al. (2007)]. Based on ﬁndings from these and other studies, in-
vestigators hypothesize that a 90e95% reduction in the nicotine
content of cigarettes may have a signiﬁcant effect on smoking
cessation and dependence potential (Sherer and Lee, 2014) without
increasing exposure to tobacco toxicants. These ﬁndings have
sparked considerable scientiﬁc interest in the potential use of low
nicotine tobacco cigarettes as a harm reduction strategy and
highlight the need for additional research (Hatsukami et al., 2013).
The physical characteristics and chemical composition of the
smoke of commercial tobacco cigarettes and reference research
cigarettes are well documented (Bodnar et al., 2012; Counts et al.,
2006; Roemer et al., 2004). In contrast, there is limited informa-
tion regarding the physical design and smoke chemistry of very low
nicotine (VLN) tobacco RCs. The chemical composition and physical
characteristics of cigarettes have been reported to inﬂuence both
the yield of smoke toxicants (Adam et al., 2010; O’Connor et al.,
2008; Stephens, 2007) and tobacco use behavior (Strasser et al.,
2006; Scherer, 1999).
In recent years, researchers have been unable to further theirnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rettes on smoking behavior as VLN cigarettes were not commer-
cially viable and thus, are no longer available. To address this deﬁcit,
the National Institute of Drug Abuse (NIDA) announced in 2013 and
2014, the availability of SPECTRUM® reduced nicotine RCs with
varying levels of nicotine (http://grants.nih.gov/grants/guide/
notice-ﬁles/NOT-DA-14-004.html). Due to the renewed interest in
reduced nicotine cigarettes and a potential nicotine product stan-
dard, we are publishing the results of two independent studies
conducted in 2001 and 2005 on smoke chemistry and in vitro
toxicology of PM USA denic RCs. These studies were conducted to
characterize the RCs before making them available to external in-
vestigators in the public health community (Domino et al., 2013;
Benowitz et al., 2007, 2012).
The objective of the research studies was to measure physical
characteristics, selected smoke constituents, and two toxicological
endpoints (cytotoxicity andmutagenicity) of PM USA denic tobacco
RCs. In addition, comparisons of PM USA denic RCs are made to the
available published literature on Quest® and SPECTRUM® reduced
nicotine content cigarettes.
2. Methods
Physical measurements and cytotoxicity and mutagenicity
testing of test research cigarettes (TCs) were conducted at PM USA
Research and Development Product Testing Laboratory and at
Philip Morris Research Laboratory, previously called Institut fur
Biologische Forschung (INBIFO). TCs were also submitted to an in-
dependent research laboratory, IIT Research Institute (IITRI, Chi-
cago, IL), for mainstream smoke (MS) chemistry, cytotoxicity and
mutagenicity testing. Assays performed were in accordance with
Good Laboratory Practice guidelines (U.S. Department of Health
and Human Services, 1996). There were slight differences in the
test methods between the two testing laboratories (differences are
noted in the supplementary material), but no substantial effect on
the overall results was observed. Results are reported on a per mg
TPM basis; results reported on a per mg tar basis and per cigarette
basis are provided in the supplementary material.
2.1. Tobacco denicotinization process
The denicotinization process used a supercritical carbon dioxide
extraction procedure (Prasad and Grubbs, 1996). Brieﬂy, a nicotine-
free carbon dioxide (CO2) solvent in the supercritical or liquid state
was fed into an extraction ﬂow system containing tobacco, and a
nicotine-rich solvent was discharged from another end of the
extraction ﬂow system. Nicotine was then entrapped from the
extracted supercooled CO2 ﬂuid and discarded. The extracted
(denic) tobacco was used in the construction of the TCs.
2.2. Cigarette construction and smoking
Three types of TCs were manufactured in 2000 (tested at
INBIFO) and 2004 (tested at IITRI) with tobacco ﬁller containing
100% denic tobacco (TC100), 50% denic tobacco and 50% unex-
tracted tobacco (TC50/50), and 100% unextracted tobacco (TC0, the
control). Nicotine content (dry weight) was approximately 2.9%,
1.5%, and 0.1% for TC0, TC50/50, and TC100, respectively.
TCs were manufactured with components (cellulose acetate
ﬁlters, papers, and adhesives) and construction processes consis-
tent with commercial US cigarette manufacturing, including casing
material (high fructose corn syrup) and a humectant (glycerol). The
tobacco blend comprised ﬂue-cured (63.3%), burley (25.7%), and
Oriental (10.9%). The TCs were targeted to be 84 mm in length
(57 mm tobacco rod, 27 mm ﬁlter) and 25 mm in circumference.Final tobacco weight was intended to be around 0.7 g. The ﬁlter
material was cellulose acetate containing 8% triacetin.
Reference cigarettes, 1R4F (used by INBIFO) and 2R4F (used by
IITRI) (Chen and Moldoveanu, 2003; Diana and Vaught, 1990) were
used as internal assay controls. The blend composition of 2R4F was
reported as 32.5% ﬂue-cured, 19.9% burley, 1.2% Maryland, 11.1%
Oriental, 27.1% reconstituted (Chen and Moldoveanu, 2003). 1R4F
and 2R4F reference cigarettes were provided by the University of
Kentucky Tobacco and Health Research Institute but had been
previously manufactured at PM USA facilities.
Following International Organization for Standardization (ISO)
standards, reference cigarettes and TCs were conditioned prior to
use for 6e7 days at target conditions of 22 C and 60% relative
humidity (International Organization for Standardization, 1999).
For MS chemistry endpoints, a single-port Borgwaldt/KC (Rich-
mond, VA) smoking machine [carbon monoxide (CO), carbon di-
oxide, nitrogen oxides (NOx), four aldehydes] or a 20-port
Borgwaldt/KC smoking machine [total particulate matter (TPM),
nicotine, water] was used. The air velocity surrounding the refer-
ence cigarettes and TCs was not monitored as speciﬁed in ISO
standard 3308 (International Organization for Standardization,
2000a) and resulted in 9.1 ± 0.06 puffs for the 2R4F reference
cigarette.
For cytotoxicity and mutagenicity testing of TPM, MS was
generated using a 20-port (by INBIFO) and 30-port (by IITRI)
Borgwaldt/KC Condor smoking machine that provided smoking
conditions (35 ml puff, of 2 s duration, taken once per minute, to a
butt length of 35 mm) in basic conformity with ISO 3308
(International Organization for Standardization, 2000a) and ISO
4387 (International Organization for Standardization, 2000b) (e.g.,
bell-shaped puff proﬁle, restricted smoking).
2.3. Physical characteristics
Physical characteristics were measured on unequilibrated 2R4F
and TCs including total cigarette length (International Organization
for Standardization, 2000b), ﬁlter length, tobacco rod length,
cigarette circumference (International Organization for
Standardization, 1998), tipping paper length, tobacco mass, ﬁlter
mass, cigarette permeability (International Organization for
Standardization, 2009), ventilation (International Organization for
Standardization, 2002), resistance to draw (RTD) (International
Organization for Standardization, 2005), and pack oven volatiles.
Lengths were measured using an electronic cigarette paper length
measuring instrument (Borgwaldt KC, Richmond, VA; Onno Sokki
Technology, Inc., Addison, IL), mass assessed using an analytical
balance (Mettler PG203-S), and circumference determined using a
non-contact, scanning laser beam cigarette test station (LaserMike,
KC Automation, Richmond, VA). The details of these methods are
provided in the supplementary material.
2.4. Mainstream smoke chemistry
MS was generated from the three TCs and the one reference
cigarette. A total of four determinations was used for each analyte.
A total of 20 cigarettes per determination was used for TPM, nico-
tine, water, 2-nitropropane, tobacco speciﬁc nitrosamines (TSNAs),
and metals. Ten cigarettes per determination were used for phe-
nols, polyaromatic hydrocarbons (PAHs), “volatiles”, and hydrogen
cyanide (HCN). Five cigarettes per determination were used for CO
and for NOx. Four cigarettes per determination were used for aro-
matic amines and aldehydes.
The amount of TPM collected on 92 mm glass ﬁber ﬁlters was
determined gravimetrically. Nicotine was determined by gas
chromatography (GC) with a nitrogen phosphorus detector in a 2-
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ternal standard (International Organization for Standardization,
2000c). Water was determined in a sample from the same 2-
propanol extract by Karl Fischer titration (International
Organization for Standardization, 1994). The methods used to
measure speciﬁc MS classes of analytes have been previously
published (Gaworski et al., 2011), and a short synopsis is available
in the supplementary material.
2.5. Cytotoxicity
In vitro cytotoxicity was determined using the neutral red (NR)
uptake method (Putnam et al., 2002) in accordance with INVITTOX
protocols (Ungar, 1992) as previously described (Gaworski et al.,
2011) and as summarized in the supplementary material. Brieﬂy,
three batches of smoke condensate were collected for each exper-
imental cigarette (12e13 cigarettes/batch) and assayed at 8 equi-
distant concentrations ranging from 2 to 21 cigarettes/l for the TPM
fraction and 3 to 30 cigarettes/l for the gas vapor phase (GVP)
fraction. Mouse embryo ﬁbroblast 3T3 cells were used in the
cytotoxicity assay in basic conformity with established guidelines
(Organisation for Economic Co-operation and Development,
1997b).
2.6. Salmonella mutagenicity
Five strains of Salmonella typhimurium (TA98, TA100, TA102,
TA1535 and TA1537) were used by IITRI and two strains (TA98 and
TA100) were used by INBIFO in the plate incorporation version of
the Salmonella reverse mutation assay (Maron and Ames, 1983) in
basic conformity with established guidelines (Organisation for
Economic Co-operation and Development, 1997a). INBIFO tested
strains with metabolic activation, whereas IITRI tested all strains
with and without metabolic activation (S9). This test is sensitive for
TPM from cigarette smoke, but the sensitivity depends on the
bacterial strain and the presence or absence of S9, a cofactor-
supplemented, postmitochondrial fraction, prepared from the
livers of rats treated with the enzyme-inducing agent Aroclor 1254.
The strains most sensitive toward TPM are TA98 and TA100, with S9
activation (Roemer et al., 2002). Two batches of MS condensate
were collected for each TC and reference cigarette and assayed at
three doses (by INBIFO) and four doses (by IITRI). Detailed methods
have been previously reported (Gaworski et al., 2011) and are
summarized in the supplementary material.
2.7. Statistical methods
Statistical comparisons were made using SigmaStat (Systat
Software, Point Richmond, CA); results were considered to be sta-
tistically signiﬁcant at p < 0.05. For the chemical analysis of MS,
analysis of variance (ANOVA) was used to compare the yields of the
TCs, excluding the 2R4F cigarette. If signiﬁcant differences were
found with the ANOVA analysis, multiple pairwise comparisons
were performed using Dunnett’s test. Since the original chemical
analysis of MS did not include a comparison of TC50/50 to TC100,
this was done post-hoc using an ANOVA followed by Pairwise
Multiple Comparison Procedures (Holm-Sidak method using Sig-
maPlot software). For all chemical constituents of MS (except
chromium and nickel) reported on a per mg of TPM basis, a pre-
viously calculated minimum detectable difference (MDD) for the
laboratory (Oldham et al., 2012) was used to evaluate the signiﬁ-
cance of the results. The MDD was calculated using the historical
assay variability of the laboratory, power (1-b) ¼ 0.8, signiﬁcance
level of a ¼ 0.05 and sample size (n). The 1/EC50 cytotoxicity values
of the TCs and reference research cigarettes were evaluated byANOVA. Mutagenicity was assessed by the post hocDunnett’s test. A
result was considered positive if a slope of a TC50/50 and TC100
was statistically signiﬁcantly different from that of TC0.
3. Results
3.1. Physical characteristics
Except for total RTD and ventilation, the physical properties of
the three TCs were all very similar, possessing less than 5% vari-
ability (Table 1). The measured parameters demonstrated that the
TCs were well-made and consistent. Measurements for reference
cigarette 2R4F also indicated consistent manufacturing practices,
but there were differences in cigarette length and rod density, and
it contained approximately 10% more tobacco than the TCs. The
mean puff counts for TC0, TC50/50, and TC100 were 10, 10.2, and
10.3, respectively, whereas the 2R4F reference cigarette resulted in
9.1 puffs per cigarette.
3.2. Smoke chemistry
Comparisons of smoke chemistry analyses were made across
cigarette types for TC0, TC50/50, and TC100 on a per mg TPM basis
(Table 2 and Fig. 1), per mg tar basis (supplementary material,
Table S1), and per cigarette basis (supplementary material,
Table S2). The results for each comparison basis are provided in
sections 3.2.1, 3.2.2, and 3.2.3, respectively. Overall, for all com-
parisons, the inclusion of increasing levels of denic tobacco resulted
in signiﬁcantly lower levels of nicotine, aldehydes, phenol, styrene,
and TSNAs. Increases were observed for aliphatic hydrocarbons,
aliphatic nitrogen compounds, aromatic amines, vinyl chloride,
NOx, benzene, toluene, and catechol.
3.2.1. Comparisons based on TPM
On a per mg TPM basis, the denic cigarettes TC50/50 and TC100
contained lower nicotine as compared with TC0 cigarettes (Table 2,
Fig. 1). Nicotine signiﬁcantly decreased directionally in a dose-
dependent manner (39e89%), while tar was signiﬁcantly
increased (4e11%) in dose-response fashion. CO was slightly
increased in TC100 but did not exceed the MDD. Although aliphatic
hydrocarbons were increased for TC50/50 and TC100, only 1,3-
butadiene in TC100 exceeded the MDD. Formaldehyde was signif-
icantly reduced (31e33%) for both TC50/50 and TC100, whereas
changes in acetaldehyde and propionaldehyde did not exceed the
MDD for either TC50/50 or TC100. Aliphatic nitrogen compounds
displayed dose-related increases (3e24%) for both TC50/50 and
TC100; however, only in TC100 did HCN and 2-nitropropane exceed
the MDD. Aromatic amines were generally increased in a dose-
related fashion for all analytes, with 2-naphthylamine and 4-
aminobiphenyl in TC100 exceeding the MDD. Vinyl chloride was
signiﬁcantly increased (36e47%) and exceeded the MDD for both
TC50/50 and TC100, while NOx increases (8e18%) exceeded the
MDD for only TC100 in a dose-related fashion. With the exception
of styrene, monocyclic aromatic compounds were generally
increased (4e23%) in a dose-related trend from TC0, and toluene
exceeded the MDD in TC100. TSNAs were generally decreased for
one or both of the TCs while N-nitrosonornicotine (NNN) and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) were sta-
tistically signiﬁcantly lower and exceeded the MDD although not in
a dose-related fashion, and many TSNAs were below the limits of
detection. Phenol was signiﬁcantly decreased (~23e40%) and
exceeded the MDD for both TC50/50 and TC100 while catechol was
signiﬁcantly increased (5e15%) and exceeded the MDD in TC100.
PAHs were only slightly elevated with the exception of benz[a]
anthracene, which was statistically signiﬁcantly elevated by 16%
Table 1
Physical characteristics of research cigarettes manufactured with various levels of denicotinized tobacco ﬁller.
Characteristic (unit) Measurement (mean ± SD)
2R4F Test cigarette
TC0 TC50/50 TC100
Total RTD (mm of water) 140 (5.90) 125 (5.02) 120 (6.95) 121 (6.13)
Length (mm) 84.2 (0.25) 83.9 (0.17) 83.7 (0.19) 83.8 (0.14)
Circumference (mm) 24.82 (0.05) 24.80 (0.07) 24.75 (0.04) 24.80 (0.03)
Weight (g) 1.055 0.9710 (0.002) 0.9760 (0.01) 0.9830 (0.01)
Paper permeability (CU) 25 (1.50) 34 (3.54) 35 (4.82) 34 (3.26)
Filter RTD (mm of water) 117 (5.80) 116 (3.45) 112 (3.24) 113 (3.18)
Filter tipping paper length (mm) 32.0 32.0 (0.001) 32.0 (0.001) 32.0 (0.001)
Filter ventilation (%) 27 (1.90) 27 (4.17) 29 (4.87) 29 (3.61)
Filler rod density (g/cc) 0.280 0.255 0.258 0.260
Tobacco weight (g) 0.785 (0.002) 0.709 (0.002) 0.713 (0.01) 0.721 (0.01)
Pack oven volatiles (%) 13.2 (0.080) 11.5 (0.10) 11.8 (0.13) 12.1 (0.0010)
Plug/paper weight (g) e 0.262 (0.002) 0.264 (0.001) 0.262 (0.002)
Butt length (mm) 35.0 35.0 35.0 35.0
RTD ¼ resistance to draw. e ¼ not determined.
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elevated by 11% in TC50/50 and approximately 5.3% lower in TC100
compared with TC0 (neither exceeded the MDD).
Arsenic was signiﬁcantly increased inMS condensate of TC50/50
and TC100 as compared with TC0 (Table 2) and exceeded the MDD.
Cadmium was signiﬁcantly elevated in TC100 as compared with
TC0 and exceeded the MDD. There were no other consistent
changes for the other metals in smoke that appeared to be corre-
lated to the composition of the TCs.
3.2.2. Comparisons based on tar
On a per mg tar basis of comparison (supplementary material,
Table S1), TPM, nicotine, water, and COwere all reduced in TC50/50
and TC100. Aldehydes were generally slightly lower, while form-
aldehyde was signiﬁcantly lower in MS condensate of TC50/50 and
TC100. Aliphatic hydrocarbons were unchanged and aliphatic ni-
trogen compounds were slightly increased. 2-Napthylamine and 4-
aminobiphenyl were signiﬁcantly increased in a dose-related
fashion, while the other aromatic amines were unchanged. We
observed slight elevations in NOx levels, signiﬁcant increases in
vinyl chloride, elevations in toluene with no other changes in
monocyclic aromatic compounds. We also observed dose-related
signiﬁcant reductions in TSNAs (NNN, NNK) and general de-
creases in PAHs with signiﬁcant reductions in benzo[a]pyrene and
indeno[1,2,3-cd]pyrene in MS condensate of TC50/50 and TC100.
Comparing TC50/50 and TC100, signiﬁcant reductions were
observed for TPM, nicotine, NNN, NNK, phenol, and benzo[a]pyrene
at the higher denic tobacco inclusion level (TC100).
Arsenic was signiﬁcantly increased inMS condensate of TC50/50
and TC100, but did not exceed the MDD (supplementary material,
Table S2).
3.2.3. Comparisons by cigarette
On a per cigarette basis (supplementary material, Table S2),
similar trends were observed. Nicotinewas signiﬁcantly reduced by
42% and 90%, respectively, for TC50/50 and TC100. TPM was
signiﬁcantly reduced approximately 5% and 12% for TC50/50 and
TC100, respectively.
Aliphatic hydrocarbons were generally unchanged, while alde-
hydes generally had small but statistically signiﬁcant reductions
except for formaldehyde, which was reduced by 34e40%. Aliphatic
nitrogen compounds were nearly unchanged. Select aromatic
amines and vinyl chloride were signiﬁcantly increased for TC50/50
and TC100. NOx and monocyclic aromatics were unchanged on a
per cigarette basis. TSNAs were generally statistically signiﬁcantlylower, phenol was reduced, catechol was unchanged, and PAHs
were generally statistically signiﬁcantly lower. The inclusion of
more denic tobacco from TC50/50 to TC100 resulted in statistically
signiﬁcant decreases in TPM and nicotine and statistically signiﬁ-
cant decreases in NNN, NNK, and all the PAHs above the limit of
quantiﬁcation except benz[a]anthracene, which was increased.
Arsenic was signiﬁcantly increased in MS condensate of TC100,
but did not exceed the MDD (supplementary material, Table S2).
3.3. Cytotoxicity
There were no statistically signiﬁcant differences in cytotoxicity
among TC0, TC50/50, and TC100 in either the GVP or particulate
fraction of the MS on a per mg TPM (Table 3). There were also no
signiﬁcant differences in cytotoxicity between TC0, TC50/50, and
TC100 in GVP or particulate fraction of MSwhen expressed on a per
mg tar or per cigarette basis (supplementary material, Table S3).
On a per mg TPM basis, the particulate fraction of MS from the
2R4F reference cigarette was statistically signiﬁcantly less cytotoxic
than that from TC0, and it was similarly less cytotoxic than TC0 on a
per mg tar basis, although not statistically signiﬁcant. However, the
cytotoxicity of GVP from TC0 and 2R4F cigarettes was similar on a
per mg tar and per mg TPM basis.
Conversely, the cytotoxicity of the particulate fraction of TC100
was the highest on a per mg TPM and per mg tar basis, without
being statistically signiﬁcant. Furthermore, it appeared that the
particulate phase of MS produces a greater cytotoxic response
(compared with GVP) whether the cigarette is a “conventional”
product (e.g., 2R4F, TC0) or denic to varying degrees (e.g., TC50/50
or TC100).
3.4. Salmonella mutagenicity
Comparisons of the mutagenic responses in Salmonella strains
TA98, TA100, TA102, TA1535, and TA1537 with the S9 fraction
showed no statistically signiﬁcant differences for MS condensate
from TC0, TC50/50, and TC100 experimental cigarettes on per mg
TPM basis (Table 4). No mutagenic activity was seen in any Sal-
monella tester strain when the S9 fraction was not used (Table 4).
Mutagenic responses for the 2R4F reference cigarette were within
normal ranges. Comparison of the mutagenic responses on a per
mg tar and per cigarette basis (supplementary material, Tables S4
and S5, respectively) in Salmonella strains TA98, TA100, TA102,
TA1535, and TA1537 with and without S9 activationwere similar to
those on a per mg TPM basis.
Table 2
Mainstream smoke constituents (per mg TPM) and group comparisons of smoke constituents (per mg TPM) in absolute terms and as a percentage of the value for TC0.
Mean ± SD (n ¼ 4).
Analyte Units 2R4F Test cigarette Value as % of TC0
TC0 TC50/50 TC100 TC50/50 TC100
FTC parameters
TPM mg 1.00 ± 0.02 1.00 ± 0.03 1.00 ± 0.03 1.00 ± 0.02 100 100
Tar mg 0.826 ± 0.014 0.816 ± 0.023 0.849 ± 0.031 0.904 ± 0.014 104 111a,b,c
Nicotine mg 0.0738 ± 0.0014 0.0984 ± 0.0026 0.0600 ± 0.0014 0.0109 ± 0.00020 61.0a,c 11.1a,b,c
Water mg 0.0955 ± 0.011 0.0856 ± 0.0039 0.0834 ± 0.0013 0.0857 ± 0.0075 97.4 100
CO mg 1.22 ± 0.042 0.904 ± 0.019 0.899 ± 0.020 0.945 ± 0.052 99.4 105a,b
Aliphatic hydrocarbons
1,3-Butadiene mg 4.17 ± 0.21 4.34 ± 0.27 4.31 ± 0.14 5.20 ± 0.46 99.3 120a,b,c
Isoprene mg 36.5 ± 2.5 44.5 ± 2.2 44.3 ± 0.80 49.5 ± 3.3 99.6 111a,b
Aldehydes
Formaldehyde mg 1.68 ± 0.22 1.14 ± 0.088 0.787 ± 0.047 0.771 ± 0.089 69.0a,c 67.6a,c
Acetaldehyde mg 53.7 ± 0.70 40.0 ± 0.45 41.0 ± 1.2 43.5 ± 1.5 103 109a,b
Acrolein mg 5.10 ± 0.15 4.12 ± 0.15 4.04 ± 0.15 4.36 ± 0.12 98.1 106b
Propionaldehyde mg 4.05 ± 0.078 3.18 ± 0.029 3.26 ± 0.071 3.40 ± 0.11 103 107b
Aliphatic nitrogen compounds
Acrylonitrile mg 1.04 ± 0.14 1.06 ± 0.10 1.12 ± 0.017 1.23 ± 0.17 106 116
HCN mg 12.2 ± 0.71 10.6 ± 0.52 11.1 ± 0.84 13.1 ± 0.59 105 124a,b,c
2-Nitropropane ng 1.23 ± 0.13 0.912 ± 0.059 0.975 ± 0.036 1.10 ± 0.10 107 121a,c
Acetamide mg 0.484 ± 0.039 0.630 ± 0.030 0.650 ± 0.034 0.720 ± 0.032 103 114a,b
Aromatic amines
o-Toluidine ng 4.55 ± 0.14 4.43 ± 0.18 4.60 ± 0.068 4.73 ± 0.15 104 107a
2-Naphthylamine ng 0.545 ± 0.022 0.554 ± 0.037 0.671 ± 0.013 0.749 ± 0.061 121a,c 135a,b,c
4-Aminobiphenyl ng 0.105 ± 0.0019 0.110 ± 0.0096 0.132 ± 0.0048 0.155 ± 0.014 120a,c 141a,b,c
o-Anisidine ng 0.249 ± 0.0054 0.207 ± 0.0088 0.220 ± 0.011 0.228 ± 0.0091 106 110a
Halogen compounds
Vinyl chloride ng 3.57 ± 0.49 1.87 ± 0.22 2.54 ± 0.24 2.75 ± 0.42 136a,c 147a,c
Inorganic compounds
NOx mg 0.0303 ± 0.00088 0.0202 ± 0.00070 0.0218 ± 0.00084 0.0238 ± 0.00085 108a 118a,b,c
Monocyclic aromatic compounds
Benzene mg 3.93 ± 0.41 3.55 ± 0.24 3.69 ± 0.030 3.94 ± 0.51 104 111
Toluene mg 5.63 ± 0.82 5.43 ± 0.49 5.92 ± 0.26 6.68 ± 0.31 109 123a,b,c
Styrene mg 0.352 ± 0.065 0.437 ± 0.015 0.433 ± 0.040 0.413 ± 0.087 99.1 94.5
N-nitrosamines
NDMA ng 0.343 ± 0.044 0.254 ± 0.038 0.188 ± 0.031 0.246 ± 0.026 74.0 96.9
NMEA ng n.d. n.d. n.d. n.d. n.d. n.d.
NDEA ng n.d. n.d. n.d. n.d. n.d. n.d.
NPRA ng n.d. n.d. n.d. n.d. n.d. n.d.
NBUA ng n.d. n.d. n.d. n.d. n.d. n.d.
NPY ng 0.546 ± 0.082 0.448 ± 0.075 0.433 ± 0.059 0.505 ± 0.037 96.7 113
NPI ng n.d. n.d. n.d. n.d. n.d. n.d.
NNN ng 12.7 ± 0.33 10.5 ± 0.59 7.56 ± 0.29 4.86 ± 0.16 72.0a,c 46.3a,b,c
NNK ng 13.8 ± 0.30 7.96 ± 0.28 6.03 ± 0.34 4.07 ± 0.40 75.8a,c 51.1a,b,c
Phenols
Phenol mg 0.901 ± 0.085 1.39 ± 0.12 1.06 ± 0.069 0.843 ± 0.031 76.3a,c 60.6a,b,c
Catechol mg 3.70 ± 0.20 3.95 ± 0.10 4.14 ± 0.12 4.54 ± 0.14 105 115a,b,c
Polycyclic aromatic hydrocarbons
Benz[a]anthracene ng 1.17 ± 0.062 0.960 ± 0.077 0.966 ± 0.11 1.11 ± 0.065 101 116,c
Benzo[b]ﬂuoranthene ng 0.495 ± 0.020 0.425 ± 0.018 0.441 ± 0.013 0.445 ± 0.011 104 105
Benzo[k]ﬂuoranthene ng 0.213 ± 0.014 0.191 ± 0.014 0.192 ± 0.013 0.195 ± 0.0071 101 102
Benzo[j]ﬂuoranthene ng 0.324 ± 0.0064 0.281 ± 0.0080 0.292 ± 0.0078 0.289 ± 0.020 104 103
Benzo[a]pyrene ng 0.671 ± 0.019 0.587 ± 0.015 0.606 ± 0.018 0.603 ± 0.014 103 103
Indeno[1,2,3-cd]pyrene ng 0.304 ± 0.0068 0.265 ± 0.010 0.270 ± 0.0084 0.268 ± 0.012 102 101
Dibenz[a,h]anthracene ng 0.025 ± 0.0020 0.019 ± 0.0028 0.021 ± 0.0018 0.018 ± 0.0024 111 94.7
5-Methylchrysene ng n.d. n.d. n.d. n.d. n.d. n.d.
Dibenzo[a,l]pyrene ng n.d. n.d. n.d. n.d. n.d. n.d.
Dibenzo[a,e]pyrene ng n.d. n.d. n.d. n.d. n.d. n.d.
Dibenzo[a,i]pyrene ng n.d. n.d. n.d. n.d. n.d. n.d.
Dibenzo[a,h]pyrene ng n.d. n.d. n.d. n.d. n.d. n.d.
Metals
Arsenic ng 0.324 ± 0.0066 0.424 ± 0.015 0.467 ± 0.0084 0.517 ± 0.0091 110a 122a,b,c
Cadmium ng 5.40 ± 0.10 5.94 ± 0.21 6.26 ± 0.21 6.68 ± 0.24 105 112a,b,c
Chromium ng n.d. n.d. n.d. n.d. n.d. n.d.
Nickel ng n.d. n.d. n.d. n.d. n.d. n.d.
Lead ng 1.29 ± 0.056 0.872 ± 0.038 0.924 ± 0.072 0.909 ± 0.019 106 104
CO ¼ carbon monoxide, FTC¼ Federal Trade Commission, HCN ¼ hydrogen cyanide, n.d. ¼ none detected (below the level of quantiﬁcation), NBUA¼N-nitrosodi-n-butyl-
amine, NDEA¼N-nitrosodiethylamine, NDMA¼N-nitrosodimethylamine, NMEA¼N-nitrosomethylethylamine, NNN¼N-nitrosonornicotine, NNK ¼ 4-(methylni-
trosamino)-1-(3-pyridyl)-1-butanone, NOx ¼ nitrogen oxides, NPI¼N-nitrosopiperidine, NPRA¼N-nitroso-N-propylamine, NPY¼N-nitrosopyrrolidine, TPM ¼ total
particulate matter.
aMean values are statistically signiﬁcantly different (p < 0.05) from the mean value for the TC0 group (excluding 2R4F).
bMean values are statistically signiﬁcantly different (p < 0.05) from the mean value for the TC50/50 group (excluding 2R4F).
cDifference between TC0 and either TC50/50 or TC100 exceeded the minimum detectable difference (MDD) using the historical assay variability of the laboratory, power (1-
b) ¼ 0.8, signiﬁcance level of a ¼ 0.05 and sample size (n). MDD for chromium and nickel were not available.
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Fig. 1. Radar plot for % changes in analyte concentrations (compared to TC0) of test cigarettes with the inclusion of various levels of denicotinized tobacco (per mg TPM basis).
Table 3
Cytotoxicity, expressed as 1/EC50, in absolute terms and as a percentage of the value for TC0.
Parameter and laboratory Run # 1/EC50 TPM (1/EC50 GVP)
2R4Fa Test cigarette Value as % of TC0
TC0 TC50/50 TC100 TC50/50 TC100
Per mg TPM
IITRI Mean 5.08 (4.59) 6.84 (3.67) 6.56 (3.62) 7.76 (3.82) 96 (99) 113 (104)
Range (þ/)b 0.30 (0.18) 0.030 (0.40) 0.61 (0.25) 0.060 (0.08)
INBIFO Mean e 8.80 (5.15) 8.28 (5.25) 9.74 (5.53) 94 (102) 111 (107)
SD e 1.45 (0.27) 0.930 (0.36) 0.190 (0.41)
INBIFO¼ Philip Morris Research Laboratory, previously called Institut fur Biologische Forschung; IITRI¼ IIT Research Institute. GVP ¼ gas vapor phase; TPM¼ total particulate
matter. e ¼ not determined.
a No data for 2R4F reference cigarette at INBIFO as this cigarette was unavailable during the study period.
b Plus/minus (range) provided because only two runs were performed.
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Several reduced nicotine cigarettes (Quest®, PM USA denic RCs,
and now recently SPECTRUM®) have been used in numerous clin-
ical studies assessing the effects of VLN cigarettes on smoking
cessation and nicotine dependence (Donny et al., 2015; Bandiera
et al., 2014; Dermody et al., 2014; Walker et al., 2014; Cummins,
2014; Hatsukami et al., 2013; Benowitz et al., 2012). However, lit-
tle has been published regarding the construction and toxicological
effect of these RCs, with the exception of Quest® (Chen et al., 2008;
Strasser et al., 2006) A comparison of Quest® and SPECTRUM® RCs,which use genetically modiﬁed (GMO) tobacco results in reduced
nicotine levels similar to that of PM USA RCs, which are made with
tobacco that is denicotinized using a supercritical CO2 extraction
method. Here, we have reported on the physical characteristics,
smoke chemistry, and in vitro cytotoxicity and mutagenicity of PM
USA TCs manufactured with 0%, 50%, and 100% inclusion of denic
tobacco ﬁller. We found signiﬁcant differences in select smoke
constituents, but overall no alterations in the in vitro toxicological
effect of denic TCs compared with control unextracted TCs, as
demonstrated by NR uptake in mammalian cells and bacterial
mutagenicity testing.
Table 4
Revertant Salmonella colonies per mg TPM, in absolute values and as a percentage of the value for TC0.
Laboratory, strain (activation) Parameter 2R4Fa Test cigarette Value as % of TC0
TC0 TC50/50 TC100 TC50/50 TC100
INBIFO
TA98 (þS9) Mean e 3944 4218 3952 107 100
Range (±) e 184 245 388
TA100 (þS9) Mean e 1321 1531 1452 116 110
Range (±) e 108.5 68.50 79.00
IITRI
TA98 (-S9) Mean 7.0 14 11 5.0 78 36
SD 2.1 2.8 7.1 4.2
TA100 (-S9) Mean 123 45.0 81.0 19.0 180 42
SD 55.2 12.7 70.7 36.1
TA102 (-S9) Mean 28 27 7.0 31 26 e
SD 29.7 26.9 50.9 74.2
TA1535 (-S9) Mean 3 5 2 1 20 40
SD 2.8 2.1 0.70 2.1
TA1537 (-S9) Mean 5 3 8 3 267 100
SD 1.4 4.2 4.9 4.9
TA98 (þS9) Mean 1549 1842 2134 2302 116 125
SD 175 454 125 55.0
TA100 (þS9) Mean 251 265 348 393 131 148
SD 95.0 108 99.0 175
TA102 (þS9) Mean 55 48 21 88 44 183
SD 4.0 35 38 23
TA1535 (þS9) Mean 1 2 1 1 e 50
SD 3.5 0.70 0.00 1.0
TA1537 (þS9) Mean 171 230 247 207 107 90
SD 14 51 37 64
INBIFO¼ Philip Morris Research Laboratory, previously called Institut fur Biologische Forschung; IITRI¼ IIT Research Institute. e ¼ not determined.
a No data for 2R4F reference cigarette at INBIFO as this cigarette was unavailable during the study period.
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The physical characteristics of the three TCs demonstrate they
were reproducibly constructed and permit a direct comparison of
MS chemistry, in vitro cytotoxicity and Salmonella mutagenicity. In
contrast, the difference in tobacco ﬁller weight, RTD, and ﬁller rod
density resulted in puff count differences between the three TCs
and the 2R4F reference cigarettes. These differences between TCs
and the 2R4F reference cigarettes indicate that normalization per
amount of TPM or tar is necessary for a valid comparison of smoke
chemistry and in vitro toxicity. There is limited published infor-
mation on the physical characteristics of VLN RCs, with the
exception of Quest® RCs (Donny et al., 2015; Strasser et al., 2006).
An assessment of physical attributes between Quest® cigarettes and
PM USA RCs illustrates a signiﬁcant difference in their cigarette
design (Strasser et al., 2006). Unlike PM USA RCs, Quest® cigarettes
contain activated charcoal (0.1 g/cigarette) in the ﬁlter, are devoid
of ﬁlter ventilation, are lower in puff count (6.4 puffs/cigarette, by
Federal Trade Commission method), and contain 20% less tobacco
mass/cigarette, all of which could potentially alter MS chemistry
(Strasser et al., 2006). The presence of activated charcoal in the
ﬁlter has been shown to signiﬁcantly reduce the yields of GVP
constituents such as monocyclic aromatic compounds, aldehydes,
aliphatic hydrocarbons, aliphatic nitrogen compounds, and cad-
mium (Gaworski et al., 2009). Recently limited physical design
parameters have been published for SPECTRUM® RCs, of which
include slightly less tobacco per cigarette (0.68 g) and similar
moisture levels (12.9%) as compared to PM USA RCs (Donny et al.,
2015). Therefore, to enable comparisons of smoke chemistry and
in vitro toxicity results between different VLN tobacco RCs, it is
essential that physical characteristics be reported. The full physical
characteristic proﬁle of SPECTRUM RCs is not known.4.2. Smoke chemistry
In the present study, we report the smoke chemistry for 47
analytes, 43 of which are included in the list of harmful and
potentially harmful constituents (HPHCs) published by US Food and
Drug Administration (FDA) in 2012 (US Food and Drug
Administration Center for Tobacco Products, 2012). The selection
of these 47 analytes was made prior to the publication of the HPHC
list and was based on the scientiﬁc literature (Gaworski et al., 2011)
and our accumulated experience studying the toxicology of ciga-
rette smoke. In addition, the biologic assessment of whole smoke or
smoke fractions would likely capture the effects of smoke constit-
uents not measured. Smoke constituent data can be presented in
various ways using several calculation bases, such as on a per mg
TPM, per mg tar, or per cigarette basis. Here we report smoke
constituent data expressed on a “per mg TPM” (Table 2), “per mg
tar” (supplementary material, Table S1) and “per cigarette” basis
(supplementary material, Table S2).
We observed signiﬁcant changes in the levels of smoke con-
stituents, including decreases in formaldehyde, nitrosamines, and
phenol and increases in aliphatic hydrocarbons, aliphatic nitrogen
compounds, aromatic amines, halogen compounds, and metals.
The FDA list of HPHCs identiﬁes and classiﬁes constituents as being
carcinogens, respiratory toxicants, cardiovascular toxicants, repro-
ductive and developmental toxicants and as addictive (US Food and
Drug Administration Center for Tobacco Products, 2012). The spe-
ciﬁc role of these toxicants in cigarette smoke-mediated disease is
unclear. However, the toxicological hazard classiﬁcation of these
constituents has been reported in the scientiﬁc literature (Burns
et al., 2008; Life Sciences Research Ofﬁce, 2004; Shields, 2002;
Thun et al., 2002). The decreasing concentrations (up to 50%) of
the TSNAs NNN and NNK observed (see Fig. 1) is presumably
directly related to the reduction of nicotine and possibly other to-
bacco alkaloids occurring during the supercritical CO2 ﬂuid
extraction process (Morgan, 2000). A number of investigators have
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as precursors in the complex nitrosation chemistry of TSNA for-
mation during curing and burning of a tobacco cigarette (Adam
et al., 2010). Reducing the nicotine precursor lowers one or
possibly more amine-containing constituents in the chemical re-
action process, thereby reducing formation of the TSNA product
(Adam et al., 2010). Chen et al. (2008) reported a similar decrease in
NNK values between Quest® 1 (low nicotine GMO tobacco) and
Quest® 3 (VLN GMO tobacco) cigarettes, but interestingly, they
observed the opposite effect for NNN values. An explanation for this
difference is currently unknown. Unlike Quest® cigarettes, a sig-
niﬁcant reduction in the MS levels of both NNN and NNK was re-
ported for SPECTRUM® VLN (0.4 mg/g nicotine) RCs as compared to
control (15.8 mg/g nicotine RCs), as characterized by the Center for
Disease Control and Prevention (Donny et al., 2015).
Chen et al. (2008) also reported that smoke constituent values
(per cigarette) from Quest® cigarettes were reduced for most ana-
lytes as compared with 2R4F reference cigarettes. However, inter-
pretation of such a comparison is difﬁcult since Quest® cigarettes
contained 30% less tobacco mass/cigarette and contained activated
charcoal. On a cigarette basis of comparison, it is plausible that a
30% decrease in tobacco mass could result in signiﬁcant reductions
in TPM and tar yield. The gas phase components of the smoke yield
may have been further reduced by the presence of activated carbon
in the ﬁlter of Quest cigarettes, which is used to scavenge volatile
organic hydrocarbons from smoke GVP (Gaworski et al., 2009). Both
of these physical attributes would obviously lead to a decrease in
smoke analyte levels. However, despite these differences in phys-
ical characteristics, a signiﬁcant increase in aromatic amines was
observed in MS from Quest® 3 cigarettes as compared with 2R4F
(similar to that observed with denic tobacco TCs). Therefore, the
observed differences in the smoke chemistry proﬁles of Quest® and
PM USA denic RCs could be attributed to both dissimilarities in
cigarette design and the processes used to reduce the nicotine
content. The full smoke chemistry proﬁle of SPECTRUM® RCs is not
known.
4.3. In vitro cytotoxicity and mutagenicity
Cigarette smoke has been repeatedly shown to be cytotoxic and
mutagenic (DeMarini et al., 2008; Patskan et al., 2008; Rickert et al.,
2007; Bombick et al., 1997). Similar assay systems were used in the
present study to measure cytotoxicity (mouse embryo ﬁbroblast
3T3 cells) and mutagenicity (Salmonella typhimurium reverse mu-
tation assay) and are in basic conformity with OECD guideline no.
432 and no. 471 respectively (Organisation for Economic Co-
operation and Development, 1997b; Organisation for Economic
Co-operation and Development, 1997a). These cytotoxicity and
mutagenicity assays have been routinely used to evaluate potential
adverse effects of ingredients added to cigarettes and “were
selected based on their known sensitivity to cigarette smoke and
their recognized predictivity for potential biological activity”
(Carmines, 2002; Roemer et al., 2002). Though most ingredient
testing studies report statistically signiﬁcant changes in various
constituents of cigarette smoke, no signiﬁcant increases in biolog-
ical activity were observed using these assay systems (Roemer
et al., 2002, 2014). In contrast, cigarettes prepared with different
tobacco types or cigarettes with tobacco electrically heated were
found to have signiﬁcant changes in smoke constituents with a
statistically signiﬁcant increase or decrease in cytotoxicity respec-
tively using the 3T3/neutral red uptake cytotoxicity assay (Roemer
et al., 2004). In the present study, use of the supercritical CO2
extraction method for removal of nicotine from the tobacco did not
signiﬁcantly inﬂuence in vitro cytotoxic or mutagenic activity of MS.
While the in vitro responses were generally not statisticallysigniﬁcant, small changes emerged suggesting a potential impact of
some smoke constituent differences for the TC100 blend compared
to the TC0 and TC50/50 blends. For example, the measured smoke
aldehydes were slightly increased on the order of 6e9%, and
formaldehyde was lower by nearly 30% while the corresponding
cytotoxicity responses for TC100 tobacco were increased slightly,
the prevailing response being a very small non-statistically signif-
icant increase in cytotoxicity. For the Ames test no consistent
pattern of changes was evident in any strainwith or without the S9
fraction, possibly due to complex interactions between some
known mutagens in smoke that increased (aromatic amines) some
very slightly (PAHs) while others decreased signiﬁcantly (NNN and
NNK). The overall conclusion from these studies is that the denic-
otinization of tobacco using a supercritical CO2 extraction method
resulted in a VLN tobacco RC that did not exhibit a change in in vitro
cytotoxicity or mutagenicity as compared to unextracted tobacco
RC or reference RC.
PM USA denic tobacco RCs, like Quest® cigarettes, when
compared to nicotine-containing RC were found to be of similar
cytotoxic and mutagenic potential, despite possessing dissimilar
smoke chemistry proﬁles (Chen et al., 2008). The in vitro toxico-
logical proﬁle of SPECTRUM® RCs is unknown. The one smoke an-
alyte that was found to be dramatically reduced by approximately
90e97% (compared with reference RCs) in all three types of VLN
tobacco RCs was nicotine, which of course was by design. These
ﬁndings appear to suggest that a dramatic reduction in smoke
nicotine content has little inﬂuence on the cytotoxic or mutagenic
potential of MS. This is somewhat surprising since previous in vitro
studies investigating nicotine per se have reported cytoprotective
and mutagenic activity (Haussmann and Fariss, 2016; Grando,
2014). These observed effects of nicotine are controversial, as
numerous conﬂicting studies have been reported (Haussmann and
Fariss, 2016). It is well established that nicotine’s biological effects
are predominately mediated by binding and activating nicotinic
acetylcholine receptors (nAChRs) in a wide variety of neuronal and
non-neuronal tissue. The presence of different types of nAChRs,
receptor up regulation and receptor desensitization inﬂuence these
complex physiological effects (Lam et al., 2016; Brown et al., 2013;
Improgo et al., 2013; Marks et al., 1985). Many types of cancer cells
express a wide variety of nAChRs (Improgo et al., 2013). As a result,
the vast majority of in vitro studies investigating the cytoprotective
potential of nicotine per se were conducted with cancer cell lines
exposed to a variety of anti-tumor treatments (Grando, 2014;
Banerjee et al., 2013; Cardinale et al., 2012; Warren et al., 2012;
Maneckjee and Minna, 1994). For example, apoptotic cell death in
human lung cancer cells exposed to opioids (Maneckjee andMinna,
1994), cisplatin (Cardinale et al., 2012) or radiation (Warren et al.,
2012) was suppressed by nicotine at levels observed with tobacco
use.
It is known that mouse embryo ﬁbroblast 3T3 cells do not ex-
press active nAChRs (Aztiria et al., 2000) and therefore we specu-
late that this cell type would be relatively unaffected by nicotine at
levels found in MS. Therefore, it is a challenge to predict the bio-
logical effect of dramatically reducing nicotine levels from tobacco
using mammalian cells that do not express active nAChRs. As
normal lung cells and tissue have been reported to express active
nAChRs (Lam et al., 2016; Fu et al., 2009), it would be interesting to
determine the cytoprotective effect of nicotine against toxicants
such as cigarette smoke condensate in human normal lung cells
expressing nAChRs. Such an assay system might prove useful in
future studies assessing the potential hazardous effect of VLN to-
bacco cigarettes.
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A published study indicates increased toxicity among blood
brain barrier endothelial cells exposed towhole smoke extract from
VLN (0.03 mg) SPECTRUM® RCs cigarettes as compared with 1R5F
and 3R4F reference RCs and commercially available Marlboro®
cigarettes (Naik et al., 2014). In addition, the researchers reported
increased nitrate and nitrite concentrations in SPECTRUM®
(0.03 mg nicotine) cigarettes (Naik et al., 2014). On the other hand,
atherosclerotic lesions of the aorta were observed to be signiﬁ-
cantly smaller in Apo E/ mice exposed to cigarette smoke from
Quest® 3 cigarettes (0.05 mg nicotine) as compared with Quest® 1
(0.6 mg nicotine) or 2R4F reference cigarettes (Catanzaro et al.,
2007). These reports suggest additional studies are required for a
better understanding of the toxicological potential of VLN tobacco
cigarettes.4.5. Limitations
The supercritical CO2 extraction process does not selectively
remove solely nicotine, but also results in the elimination of other
tobacco alkaloids and plant waxes (Morgan, 2000). It is well known
that carbohydrate-containing tobacco leaf polymers, lipids, and
waxes are responsible, in part, for formaldehyde yields in cigarette
smoke (Piade et al., 2013). It is interesting to note that formalde-
hyde yields were dramatically reduced using denic tobacco ciga-
rettes (Table 2, Fig. 1). Therefore, non-nicotine associated changes
in the tobacco resultant from the extraction procedure, may inﬂu-
ence the toxicological proﬁle of RCs containing denic tobacco. In
addition, the RCs used in the studies conducted by INBIFO and IITRI
were manufactured using the same process, but at different times.
To account for manufacturing batch differences, reference ciga-
rettes such as 1R4F and 2R4F were included as internal assay
controls and were compared with historical data. Here, we provide
data from analytical and in vitro toxicology studies conducted in the
early 2000s on TCs manufactured with various amounts of denic
tobacco.5. Conclusions
Removal of nicotine from the tobacco via use of a supercritical
CO2 extraction process resulted in several alterations in the
chemical composition of MS, but the changes did not modify bio-
logical activity as measured by the cytotoxicity and mutagenicity
assays used. The physical characteristics of the TCs were very
reproducible and similar to 2R4F, but differed from that of Quest® 3
cigarettes. Unlike PM USA denic RCs, Quest® 3 cigarettes possess
ventilation, 20% more tobacco mass/cigarette, and they contain
activated carbon in the ﬁlter. As more data becomes available it will
be interesting to see how the physical and chemical proﬁles of
SPECTRUM® RCs compare with those of other genetically modiﬁed
VLN RCs (Quest® 3) and nicotine-extracted RCs such as PM USA
denic RCs.Funding
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